The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG‐negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression

The Nijmegen breakage syndrome (NBS1) gene was suggested as a prostate cancer susceptibility gene. This study was undertaken to determine, whether NBS1 expression is linked to clinically or molecularly relevant subgroups of prostate cancer. NBS1 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancer specimens. NBS1 expression was absent or only weakly detectable in benign prostate. In prostate cancers, NBS1 expression was found in 81.3% of interpretable tumors and was considered strong in 41.3% of cases. NBS1 upregulation was tightly linked to ERG‐positive cancers (p < 0.0001). Within ERG‐negative cancers, strong NBS1 immunostaining was linked to advanced pathological tumor stage, high Gleason grade, and positive nodal status (p < 0.0001 each), while high NBS1 immunostaining was only weakly associated with advanced pathological tumor stage in ERG‐positive cancers (p = 0.0099). A comparison with chromosomal deletions revealed a strong NBS1 upregulation in PTEN‐deleted cancers, while deletions of 3p13, 5q21 and 6q15 did not affect NBS1 expression. High NBS1 expression was linked to biochemical recurrence in ERG‐negative and PTEN non‐deleted cancers (p < 0.0001), which was largely driven by high KPNA2 karyopherin alpha 2 expression. In conclusion, our study identifies an association of NBS1 expression with surrogates of genomic instability in prostate cancer including TMPRSS2‐ERG rearrangements and PTEN deletion. The prognostic impact of NBS1 expression in ERG‐negative, PTEN non‐deleted cancers was dependent of the expression status of its interaction partner KPNA2.

[1]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[2]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[3]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[4]  K. Khanna,et al.  Inactivation of ATM/ATR DNA Damage Checkpoint Promotes Androgen Induced Chromosomal Instability in Prostate Epithelial Cells , 2012, PloS one.

[5]  A Jakubowska,et al.  An inherited NBN mutation is associated with poor prognosis prostate cancer , 2012, British Journal of Cancer.

[6]  J. Carpten,et al.  Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer , 2012, Familial Cancer.

[7]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[8]  R. Medeiros,et al.  DNA repair system and prostate cancer progression: the role of NBS1 polymorphism (rs1805794). , 2012, DNA and cell biology.

[9]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[10]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[11]  G. Kristiansen,et al.  KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy , 2011, Clinical Cancer Research.

[12]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[13]  M. Weitzman,et al.  The MRN complex in double‐strand break repair and telomere maintenance , 2010, FEBS letters.

[14]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[15]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[16]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[17]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[18]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[19]  J. Cerhan,et al.  Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[20]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[21]  H. Tauchi,et al.  Nijmegen breakage syndrome and functions of the responsible protein, NBS1. , 2006, Genome dynamics.

[22]  Kou-Juey Wu,et al.  Importin KPNA2 Is Required for Proper Nuclear Localization and Multiple Functions of NBS1* , 2005, Journal of Biological Chemistry.

[23]  R. Parsons,et al.  PTEN Loss Inhibits CHK1 to Cause Double Stranded-DNA Breaks in Cells , 2005, Cell cycle.

[24]  T. Pandita,et al.  Lack of PTEN sequesters CHK1 and initiates genetic instability. , 2005, Cancer cell.

[25]  A. Jakubowska,et al.  NBS1 Is a Prostate Cancer Susceptibility Gene , 2004, Cancer Research.

[26]  Johnson M Liu,et al.  Chromosomal breakage syndromes and the BRCA1 genome surveillance complex. , 2001, Trends in molecular medicine.

[27]  J. Carpten,et al.  A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Matthias Platzer,et al.  Nibrin, a Novel DNA Double-Strand Break Repair Protein, Is Mutated in Nijmegen Breakage Syndrome , 1998, Cell.

[29]  John R Yates,et al.  The hMre11/hRad50 Protein Complex and Nijmegen Breakage Syndrome: Linkage of Double-Strand Break Repair to the Cellular DNA Damage Response , 1998, Cell.

[30]  H. Moch,et al.  Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.

[31]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[32]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[33]  J. Weber,et al.  Genetic mapping of a locus predisposing to human colorectal cancer. , 1993, Science.

[34]  H. Lynch,et al.  Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II): a common genotype linked to oncogenes? , 1985, Medical hypotheses.

[35]  R. Taalman,et al.  A NEW CHROMOSOMAL INSTABILITY DISORDER: THE NIJMEGEN BREAKAGE SYNDROME , 1981, Acta paediatrica Scandinavica.

[36]  G. Sauter,et al.  High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy , 2014, Modern Pathology.

[37]  J. Gardovskis,et al.  Epidemiologic, clinical, and molecular characteristics of hereditary prostate cancer in Latvia. , 2011, Medicina.

[38]  Michael S. Becker,et al.  The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. , 2010, Advances in immunology.

[39]  Ronald Simon,et al.  Immunohistochemical analysis of tissue microarrays. , 2010, Methods in molecular biology.

[40]  Ronald Simon,et al.  Recipient block TMA technique. , 2010, Methods in molecular biology.

[41]  Ronald Simon,et al.  Tissue Microarrays , 2010, Methods in Molecular Biology.